Media & Technology
Astra Veda Corporation (OTCMKTS: ASTA) Powerful Runner as Tech Pioneer Nears Pink Current & Ballistic Barrier Products Inc. (BBP) JV Gains Traction
Astra Veda Corporation (OTCMKTS: ASTA) continues to move northbound in a hurry recently eclipsing the $0.01 mark and moving well into copper land. The stock has emerged in recent weeks as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation ASTA is moving steadily northbound with many new investors buying in every day. Microcapdaily reported on ASTA when the stock was still trading in the double zeroes stating at the time: “ASTA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – and ASTA has much stronger fundamentals then Tesoro ever did.” ASTA is focused on becoming fully reporting and moving to “pink current” recently reporting its OTCIQ application has been officially approved by the OTC Markets Group. The Companies draft OTC Markets disclosure is being reviewed by a highly qualified Certified Public Accountant (CPA), then will be reviewed by a designated attorney to fulfill the requirement of Attorney Letter with Respect to Current Information. Once these steps are completed, ASTA will upload the finalized disclosures to be reviewed and accepted by the OTC Markets Group.
Big things are happening at ASTA since new CEO James M. Davis, a high-level executive who played a key rose in the founding of High-Speed Access Corporation contributing to the more than Two-Billion-dollar initial public offering on NASDAQ became the controlling shareholder of the Company. Punchzee is a joint venture development effort between Paranotek, LLC and a group of private investors. Punchzee is a disruptive data-driven project management and team communication platform for the construction industry, property management companies and home developers and inspectors. Punchzee currently manages over 100,000 critical life, safety and fire certification and inspection tasks for companies throughout the eastern United States, including the NYPD and hospital systems through the area. More recently ASTA formed a jv to manufacture Bullet BarrierTM Products. The new entity is called Ballistic Barrier Products Inc. (BBP), and responsible for product development, manufacturing and sales support for ballistic resistant window and door coverings fulfilling the incredible demand for orders. A facility has already been identified in the heart of the textile industry in the Southeastern US with close regional support for materials, equipment, and skilled labor.
Astra Veda Corporation (OTCMKTS: ASTA) operating out of Aurora, Colorado co-founds technology companies and incubate them to maturity to generate revenue for Astra and its partners. The Company builds winning products in a capital-efficient way, using design thinking, lean startup and agile development methodologies. The Company changed their name to ASTA from WRFX back in June 2019.
A
STA operating subsidiaries are Paranotek; a global innovation company focused on developing mobile apps and licensing robust technologies that increase personal and corporate information privacy through breakthrough advancements in encryption. Paranotek began as a Finnish technology and design company working together with US partners. Paranotek has developed a disruptive and future-proof encryption technology called Parano™ that can be integrated into existing software and apps for everyday life.
Punchzee is a joint venture development effort between Paranotek, LLC and a group of private investors. Punchzee is a disruptive data-driven project management and team communication platform for the construction industry, property management companies and home developers and inspectors. Punchzee currently manages over 100,000 critical life, safety and fire certification and inspection tasks for companies throughout the eastern United States, including the NYPD and hospital systems through the area.
ASTA has a strong management team behind it; the Company’s CEO James M. Davis who recentlhy took control of the Company from Bradley Martin Listermann is a high-level executive who played a key rose in the founding of High-Speed Access Corporation contributing to the more than Two-Billion-dollar initial public offering on NASDAQ. A year later, the company was later purchased by Charter Communications owned by Microsoft co-founder Paul Allen. In addition to his academic achievements in Cognitive Human Behavior from the University of Maine, he maintains an active Top-Secret clearance from the US government. Mick continues advising government agencies on a variety of confidential initiatives as a highly compensated expert (HCE).
In May the Compay made a substantial investment in a joint venture to manufacture Bullet BarrierTM Products. The new entity is called Ballistic Barrier Products Inc. (BBP), and responsible for product development, manufacturing and sales support for ballistic resistant window and door coverings fulfilling the incredible demand for orders. A facility has been identified in the heart of the textile industry in the Southeastern US with close regional support for materials, equipment, and skilled labor. BBP will be selling to residential and commercial customers as well as schools and government entities both domestically and abroad in the coming months. Partners in the venture include Astra Veda Corporation, Egres Enterprises and Rift Management Inc. (RMI). Astra is focused on co-founding technology companies and incubate them to success.
https://twitter.com/WoShaun/status/1430208368866742278
To Find out the inside Scoop on ASTA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Microcapdaily first reported on ASTA on August 3 when the stock was still in the dobule zeroes atating at the time: Astra Veda Corporation (OTCMKTS: ASTA) is moving northbound with power in recent days having surpassed previous highs the stock is now on a blue-sky breakout. ASTA is quickly emerging as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation ASTA is moving steadily northbound with many new investors buying in every day. ASTA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – and ASTA has much stronger fundamentals then Tesoro ever did.
Earlier this month Astra reported its OTCIQ application has been officially approved by the OTC Markets Group. Chairman and CEO Mick Davis beamed with pride stating, thanks to the tireless efforts of our entire team, friends, family and generous support from a key investor, together we transformed the Company from its crooked and shady past to its bright and straightforward trajectory ahead. To answer the most pressing question from new shareholders, Davis said, we will meet the S.E.C. Rule 15c-211 amendment requirements with updated OTC disclosures before the deadline. We have a prosperous horizon ahead coupled with our focused strategy. We are not deviating from that course of action no matter the rumor or emotion of the day.
Our draft OTC Markets disclosure is being reviewed by a highly qualified Certified Public Accountant (CPA), then will be reviewed by a designated attorney to fulfill the requirement of Attorney Letter With Respect to Current Information. Once these steps are completed, we will upload the finalized disclosures to be reviewed and accepted by the OTC Markets Group. The Company has accomplished our foundational objective in creating a rock-solid GAAP accounting ledger from the ashes of the past. We have created extensive financial processes and procedures preparing for our first audit in 2022. We are now laser focused on revenue production with our subsidiary and joint ventures. We have bold objectives with innovative opportunities. Revenue development activities is under way with our investment affiliates which will drive the Company toward a dividend enriched future.
Thank you again to all the long-term shareholders for your faith while we remained dark. This strategy was purposeful to prevent additional share dilution and manipulation by bad actors empowered by the former leadership during our recovery and rehabilitation period. The future for the Astra Veda Corporation is very clear. The last barriers to success are now behind us. We look forward to sharing tremendous news with the public as facts emerge in the coming days.
$ASTA pic.twitter.com/Wyan684OeG
— Collective Bulls (@CarlFMerz) August 20, 2021
For More on ASTA Subscribe Right Now!
ASTA continues to move northbound in a hurry recently eclipsing the $0.01 mark and moving well into copper land. The stock has emerged in recent weeks as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation ASTA is moving steadily northbound with many new investors buying in every day. Microcapdaily reported on ASTA when the stock was still trading in the double zeroes stating at the time: “ASTA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – and ASTA has much stronger fundamentals then Tesoro ever did.” ASTA is focused on becoming fully reporting and moving to “pink current” recently reporting its OTCIQ application has been officially approved by the OTC Markets Group. The Companies draft OTC Markets disclosure is being reviewed by a highly qualified Certified Public Accountant (CPA), then will be reviewed by a designated attorney to fulfill the requirement of Attorney Letter with Respect to Current Information. Once these steps are completed, ASTA will upload the finalized disclosures to be reviewed and accepted by the OTC Markets Group. Big things are happening at ASTA since new CEO James M. Davis, a high-level executive who played a key rose in the founding of High-Speed Access Corporation contributing to the more than Two-Billion-dollar initial public offering on NASDAQ became the controlling shareholder of the Company. Punchzee is a joint venture development effort between Paranotek, LLC and a group of private investors. Punchzee is a disruptive data-driven project management and team communication platform for the construction industry, property management companies and home developers and inspectors. Punchzee currently manages over 100,000 critical life, safety and fire certification and inspection tasks for companies throughout the eastern United States, including the NYPD and hospital systems through the area. More recently ASTA formed a jv to manufacture Bullet BarrierTM Products. The new entity is called Ballistic Barrier Products Inc. (BBP), and responsible for product development, manufacturing and sales support for ballistic resistant window and door coverings fulfilling the incredible demand for orders. A facility has already been identified in the heart of the textile industry in the Southeastern US with close regional support for materials, equipment, and skilled labor. We will be updating on ASTA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ASTA.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in TXTM either long or short and we have not been compensated for this article.
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX.
All I did was follow the system.
It has a small float.
Fresh meet never pumped before.
Big News out.
Giant volume.
Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz— Trader Brian Jones (@MasterBJones) June 2, 2023
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
— Jake Weber (@BioStockAnalyst) June 2, 2023
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
— Jake Weber (@BioStockAnalyst) June 2, 2023
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.
Revolutionizing User Experience and Driving Stock Surge
$onfo in news and float are lit pic.twitter.com/7afKMOfdz2
— …frankyboyz… (@frankyboyz77) May 26, 2023
With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.
To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ONFO just took the elevator to the top!
Now just waiting on $CYTO pic.twitter.com/OfJgNb1ty0
— 💎 DBR 💎 (@dbr_land) May 26, 2023
Evaluating Financial Performance
While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.
*says the word "AI" once
* $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2
— Commonstock (@JoinCommonstock) May 26, 2023
Investment Outlook and Future Prospects
Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.
$onfo in news and float are lit pic.twitter.com/Q8eIveRfgd
— …frankyboyz… (@frankyboyz77) May 26, 2023
About MightyDeals.com
Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.
About Onfolio Holdings Inc.
Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.
$ONFO #Ai have you seen this stock? Just came out with a competitive AI software that will fight against the tech kings #microsoft #google
— Don’t Look Down (@M_1Ball) May 26, 2023
Conclusion
Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.
$ONFO – "AI program" is laughable. Check it out on https://t.co/0LdCQCWC28. I searched for "shoes" and flower bouquets showed up. I put in a search for "dogs" and african animals came up.
Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr
— Adam Gefvert, CFA (@Shiningboy) May 26, 2023
We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership
Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
